Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Comparative Network Reconstruction using mixed integer programming.

Bosdriesz E, Prahallad A, Klinger B, Sieber A, Bosma A, Bernards R, Blüthgen N, Wessels LFA.

Bioinformatics. 2018 Sep 1;34(17):i997-i1004. doi: 10.1093/bioinformatics/bty616.

2.

Reverse engineering gene regulatory networks by modular response analysis - a benchmark.

Klinger B, Blüthgen N.

Essays Biochem. 2018 Oct 26;62(4):535-547. doi: 10.1042/EBC20180012. Print 2018 Oct 26. Review.

PMID:
30315094
3.

Modelling Signalling Networks from Perturbation Data.

Dorel M, Klinger B, Gross T, Sieber A, Prahallad A, Bosdriesz E, Wessels L, Blüthgen N.

Bioinformatics. 2018 Jun 19. doi: 10.1093/bioinformatics/bty473. [Epub ahead of print]

PMID:
29931053
4.

Perturbation-response genes reveal signaling footprints in cancer gene expression.

Schubert M, Klinger B, Klünemann M, Sieber A, Uhlitz F, Sauer S, Garnett MJ, Blüthgen N, Saez-Rodriguez J.

Nat Commun. 2018 Jan 2;9(1):20. doi: 10.1038/s41467-017-02391-6.

5.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M, Klinger B, Blüthgen N.

Mol Syst Biol. 2017 Sep 25;13(9):944. doi: 10.15252/msb.20177986. No abstract available.

6.

An immediate-late gene expression module decodes ERK signal duration.

Uhlitz F, Sieber A, Wyler E, Fritsche-Guenther R, Meisig J, Landthaler M, Klinger B, Blüthgen N.

Mol Syst Biol. 2017 May 3;13(5):928. doi: 10.15252/msb.20177554. Erratum in: Mol Syst Biol. 2017 Sep 25;13(9):944.

7.

Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models.

Eduati F, Doldàn-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F, Dorel M, Garnett MJ, Blüthgen N, Saez-Rodriguez J.

Cancer Res. 2017 Jun 15;77(12):3364-3375. doi: 10.1158/0008-5472.CAN-17-0078. Epub 2017 Apr 5.

8.

The role of the cancer stem cell marker CD271 in DNA damage response and drug resistance of melanoma cells.

Redmer T, Walz I, Klinger B, Khouja S, Welte Y, Schäfer R, Regenbrecht C.

Oncogenesis. 2017 Jan 23;6(1):e291. doi: 10.1038/oncsis.2016.88.

9.

Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A.

Rohwer N, Bindel F, Grimm C, Lin SJ, Wappler J, Klinger B, Blüthgen N, Du Bois I, Schmeck B, Lehrach H, de Graauw M, Goncalves E, Saez-Rodriguez J, Tan P, Grabsch HI, Prigione A, Kempa S, Cramer T.

Oncotarget. 2016 Feb 9;7(6):6693-710. doi: 10.18632/oncotarget.6793.

10.

Hypoxia-induced gene expression results from selective mRNA partitioning to the endoplasmic reticulum.

Staudacher JJ, Naarmann-de Vries IS, Ujvari SJ, Klinger B, Kasim M, Benko E, Ostareck-Lederer A, Ostareck DH, Bondke Persson A, Lorenzen S, Meier JC, Blüthgen N, Persson PB, Henrion-Caude A, Mrowka R, Fähling M.

Nucleic Acids Res. 2015 Mar 31;43(6):3219-36. doi: 10.1093/nar/gkv167. Epub 2015 Mar 8.

11.

Computer-assisted curation of a human regulatory core network from the biological literature.

Thomas P, Durek P, Solt I, Klinger B, Witzel F, Schulthess P, Mayer Y, Tikk D, Blüthgen N, Leser U.

Bioinformatics. 2015 Apr 15;31(8):1258-66. doi: 10.1093/bioinformatics/btu795. Epub 2014 Nov 29.

PMID:
25433699
12.

Consequences of feedback in signal transduction for targeted therapies.

Klinger B, Blüthgen N.

Biochem Soc Trans. 2014 Aug;42(4):770-5. doi: 10.1042/BST20140130. Review.

PMID:
25109956
13.

Network quantification of EGFR signaling unveils potential for targeted combination therapy.

Klinger B, Sieber A, Fritsche-Guenther R, Witzel F, Berry L, Schumacher D, Yan Y, Durek P, Merchant M, Schäfer R, Sers C, Blüthgen N.

Mol Syst Biol. 2013;9:673. doi: 10.1038/msb.2013.29.

14.

Multilevel regulation of HIF-1 signaling by TTP.

Fähling M, Persson AB, Klinger B, Benko E, Steege A, Kasim M, Patzak A, Persson PB, Wolf G, Blüthgen N, Mrowka R.

Mol Biol Cell. 2012 Oct;23(20):4129-41. doi: 10.1091/mbc.E11-11-0949. Epub 2012 Aug 23.

15.

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS.

Stelniec-Klotz I, Legewie S, Tchernitsa O, Witzel F, Klinger B, Sers C, Herzel H, Blüthgen N, Schäfer R.

Mol Syst Biol. 2012;8:601. doi: 10.1038/msb.2012.32.

16.

Discovering causal signaling pathways through gene-expression patterns.

Parikh JR, Klinger B, Xia Y, Marto JA, Blüthgen N.

Nucleic Acids Res. 2010 Jul;38(Web Server issue):W109-17. doi: 10.1093/nar/gkq424. Epub 2010 May 21.

17.

A multilocular radiolucency. Botryoid odontogenic cyst.

Chi AC, Neville BW, Klinger BJ.

J Am Dent Assoc. 2007 Aug;138(8):1102-3. No abstract available.

PMID:
17670878
18.

The product space conditions the development of nations.

Hidalgo CA, Klinger B, Barabási AL, Hausmann R.

Science. 2007 Jul 27;317(5837):482-7.

19.

The mating pair stabilization protein, TraN, of the F plasmid is an outer-membrane protein with two regions that are important for its function in conjugation.

Klimke WA, Rypien CD, Klinger B, Kennedy RA, Rodriguez-Maillard JM, Frost LS.

Microbiology. 2005 Nov;151(Pt 11):3527-40.

PMID:
16272376
20.
21.
22.

The disruptive behavior disorders in the psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1999 May-Jun;21(3):214-9.

PMID:
10378115
23.

Patients with Laron syndrome have Osteopenia/Osteoporosis.

Laron Z, Klinger B, Silbergeld A.

J Bone Miner Res. 1999 Jan;14(1):156-7. No abstract available.

24.

Development of hyperandrogenism during treatment with insulin-like growth factor-I (IGF-I) in female patients with Laron syndrome.

Klinger B, Anin S, Silbergeld A, Eshet R, Laron Z.

Clin Endocrinol (Oxf). 1998 Jan;48(1):81-7.

PMID:
9509072
26.

County drift: a type of geographic mobility of chronic psychiatric patients.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1998 Jan;20(1):44-7.

PMID:
9506253
27.
28.

[Nursing anamnesis--determining the emphasis].

Klinger B.

Kinderkrankenschwester. 1997 Aug;16(8):320-2. German. No abstract available.

PMID:
9370599
29.

Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree.

Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, Laron Z.

J Pediatr Endocrinol Metab. 1997 May-Jun;10(3):265-74.

PMID:
9388817
30.

Growth hormone increases and insulin-like growth factor-I decreases circulating lipoprotein(a)

Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.

Eur J Endocrinol. 1997 Apr;136(4):377-81.

PMID:
9150696
31.

Growth during and 2 years after stopping GH treatment in prepubertal children with idiopathic short stature.

Laron Z, Klinger B, Anin S, Pertzelan A, Lilos P.

J Pediatr Endocrinol Metab. 1997 Mar-Apr;10(2):191-6.

PMID:
9364352
32.

Time study of psychiatric emergency service evaluations.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1997 Jan;19(1):1-4.

PMID:
9034804
34.

Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions.

Lindner P, Bauer K, Krebber A, Nieba L, Kremmer E, Krebber C, Honegger A, Klinger B, Mocikat R, Plückthun A.

Biotechniques. 1997 Jan;22(1):140-9.

35.

Characteristics of managed care patients in a psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

Psychiatr Serv. 1996 Nov;47(11):1259-61.

PMID:
8916248
36.

Insulin-like growth factor-I raises serum procollagen levels in children and adults with Laron syndrome.

Klinger B, Jensen LT, Silbergeld A, Laron Z.

Clin Endocrinol (Oxf). 1996 Oct;45(4):423-9.

PMID:
8959080
37.

Insulin-like growth factor-I decreases serum lipoprotein (a) during long-term treatment of patients with Laron syndrome.

Laron Z, Wang XL, Klinger B, Silbergeld A, Wilcken DE.

Metabolism. 1996 Oct;45(10):1263-6.

PMID:
8843182
38.

Growth hormone treatment increases circulating lipoprotein(a) in children with chronic renal failure.

Laron Z, Wang XL, Klinger B, Silbergeld A, Davidovits M, Eisenstein B, Wilcken DE.

J Pediatr Endocrinol Metab. 1996 Sep-Oct;9(5):533-7.

PMID:
8961129
39.
40.

Acute intoxication and substance abuse among patients presenting to a psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

Gen Hosp Psychiatry. 1996 May;18(3):183-91.

PMID:
8739011
41.

Intranasal administration of the GHRP hexarelin accelerates growth in short children.

Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A.

Clin Endocrinol (Oxf). 1995 Nov;43(5):631-5.

PMID:
8548949
42.
43.

Three year IGF-I treatment of children with Laron syndrome.

Klinger B, Laron Z.

J Pediatr Endocrinol Metab. 1995 Jul-Sep;8(3):149-58.

PMID:
8521188
44.

Crisis hospitalization in a psychiatric emergency service.

Breslow RE, Klinger BI, Erickson BJ.

New Dir Ment Health Serv. 1995 Fall;(67):5-12.

PMID:
7476810
45.

Renal function in Laron syndrome patients treated by insulin-like growth factor-I.

Klinger B, Laron Z.

Pediatr Nephrol. 1994 Dec;8(6):684-8.

PMID:
7696105
46.

IGF-I treatment of adult patients with Laron syndrome: preliminary results.

Laron Z, Klinger B.

Clin Endocrinol (Oxf). 1994 Nov;41(5):631-8.

PMID:
7530175
47.

Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).

Laron Z, Frenkel J, Gil-Ad I, Klinger B, Lubin E, Wuthrich P, Boutignon F, Lengerts V, Deghenghi R.

Clin Endocrinol (Oxf). 1994 Oct;41(4):539-41.

PMID:
7955465
48.

Comparative effects of GH, IGF-I and insulin on serum sex hormone binding globulin.

Gafny M, Silbergeld A, Klinger B, Wasserman M, Laron Z.

Clin Endocrinol (Oxf). 1994 Aug;41(2):169-75.

PMID:
7923821
49.

Serum growth hormone-binding protein (GHBP) activity is decreased by administration of insulin-like growth factor I in three Laron syndrome siblings with normal GHBP.

Silbergeld A, Klinger B, Keret R, Eshet R, Almonté AS, Laron Z.

Proc Soc Exp Biol Med. 1994 Jul;206(3):324-7.

PMID:
8016174
50.

Laron syndrome: clinical features, molecular pathology and treatment.

Laron Z, Klinger B.

Horm Res. 1994;42(4-5):198-202.

PMID:
7868073

Supplemental Content

Loading ...
Support Center